Valneva SE (VALN) Research & Development (2021 - 2026)
Valneva SE (VALN) posted quarterly Research & Development of -$17.3 million for Q1 2026, down 1.75% year-on-year from -$17.6 million in Q1 2025, and down 110.49% on a QoQ basis from $165.0 million in Q4 2025.
Valneva SE (VALN) Research & Development (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Research & Development for 6 consecutive years, with -$17.3 million the latest figure, recorded in Q1 2026.
- Quarterly Research & Development fell 1.75% year-over-year to -$17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.8 million (up 17.59% YoY) and the FY2025 annual result came in at $97.1 million, up 15.05% from the prior year.
- Research & Development declined to -$17.3 million in Q1 2026 per VALN's latest filing, from $165.0 million in the prior quarter.
- Over the last five years, Research & Development for VALN reached as high as $205.2 million in Q4 2022 and fell as low as -$35.5 million in Q2 2022.
- A 5-year average of $20.7 million and a median of -$17.3 million in 2026 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 61.81% — and 2025, when it slumped 44.5%.
- Year by year, Research & Development stood at $205.2 million in 2022, then slumped by 43.37% to $116.2 million in 2023, then advanced by 20.17% to $139.6 million in 2024, then climbed by 18.19% to $165.0 million in 2025, then sank by 110.49% to -$17.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$17.3 million, $165.0 million, and -$31.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -17.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.31 Mn |
| Dec 31, 2025 | 165.04 Mn |
| Sep 30, 2025 | -31.05 Mn |
| Jun 30, 2025 | -19.90 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | 139.64 Mn |
| Sep 30, 2024 | -21.49 Mn |
| Jun 30, 2024 | -18.84 Mn |
| Mar 31, 2024 | -14.94 Mn |
| Dec 31, 2023 | 116.20 Mn |
| Sep 30, 2023 | -18.48 Mn |
| Jun 30, 2023 | -13.56 Mn |
| Mar 31, 2023 | -16.01 Mn |
| Dec 31, 2022 | 205.18 Mn |
| Sep 30, 2022 | -26.74 Mn |
| Jun 30, 2022 | -35.50 Mn |
| Mar 31, 2022 | -23.54 Mn |
| Dec 31, 2021 | 330.60 Mn |
| Sep 30, 2021 | -43.81 Mn |
| Jun 30, 2021 | -58.04 Mn |